SR 1664CAS# 1338259-05-4 |
2D Structure
- PA-824
Catalog No.:BCC1106
CAS No.:187235-37-6
- Clofazimine
Catalog No.:BCC4651
CAS No.:2030-63-9
- 5-hydroxypyrazine-2-carboxylic acid
Catalog No.:BCC1311
CAS No.:34604-60-9
- Nitazoxanide
Catalog No.:BCC3824
CAS No.:55981-09-4
- Sodium 4-Aminosalicylate
Catalog No.:BCC4609
CAS No.:6018-19-5
- Rifapentine
Catalog No.:BCC4937
CAS No.:61379-65-5
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 1338259-05-4 | SDF | Download SDF |
PubChem ID | 53239854 | Appearance | Powder |
Formula | C33H29N3O5 | M.Wt | 547.6 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO and to 100 mM in ethanol | ||
Chemical Name | 2-[4-[[2,3-dimethyl-5-[[(1S)-1-(4-nitrophenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid | ||
SMILES | CC1=C(N(C2=C1C=C(C=C2)C(=O)NC(C)C3=CC=C(C=C3)[N+](=O)[O-])CC4=CC=C(C=C4)C5=CC=CC=C5C(=O)O)C | ||
Standard InChIKey | IIJDFXNUWZTHIM-NRFANRHFSA-N | ||
Standard InChI | InChI=1S/C33H29N3O5/c1-20-22(3)35(19-23-8-10-25(11-9-23)28-6-4-5-7-29(28)33(38)39)31-17-14-26(18-30(20)31)32(37)34-21(2)24-12-15-27(16-13-24)36(40)41/h4-18,21H,19H2,1-3H3,(H,34,37)(H,38,39)/t21-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Antidiabetic agent; binds to PPARγ and potently inhibits Cdk5-mediated PPARγ phosphorylation (IC50 = 80 nM; Ki = 28.67 nM) without exhibiting PPARγ agonist activity. Does not inhibit Cdk5-dependent phosphorylation of Rb. Reduces fasting insulin levels and improves insulin sensitivity in a mouse model of diabetes. |
SR 1664 Dilution Calculator
SR 1664 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.8262 mL | 9.1308 mL | 18.2615 mL | 36.523 mL | 45.6538 mL |
5 mM | 0.3652 mL | 1.8262 mL | 3.6523 mL | 7.3046 mL | 9.1308 mL |
10 mM | 0.1826 mL | 0.9131 mL | 1.8262 mL | 3.6523 mL | 4.5654 mL |
50 mM | 0.0365 mL | 0.1826 mL | 0.3652 mL | 0.7305 mL | 0.9131 mL |
100 mM | 0.0183 mL | 0.0913 mL | 0.1826 mL | 0.3652 mL | 0.4565 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- LIMKi 3
Catalog No.:BCC7972
CAS No.:1338247-35-0
- Manninotriose
Catalog No.:BCN8488
CAS No.:13382-86-0
- Dysolenticin J
Catalog No.:BCN7497
CAS No.:1337973-08-6
- GSK2656157
Catalog No.:BCC4983
CAS No.:1337532-29-2
- GSK2606414
Catalog No.:BCC1606
CAS No.:1337531-36-8
- Suavioside A
Catalog No.:BCN6963
CAS No.:133740-37-1
- Ebenifoline E-II
Catalog No.:BCN3097
CAS No.:133740-16-6
- GSK 2193874
Catalog No.:BCC8009
CAS No.:1336960-13-4
- 1-Allyl-3,5-Dimethylpyrazole
Catalog No.:BCC8450
CAS No.:13369-74-9
- Exoticin
Catalog No.:BCN6182
CAS No.:13364-94-8
- 2-Aminoisonicotinic acid
Catalog No.:BCC8550
CAS No.:13362-28-2
- 2-Ethyl-2,6,6-trimethylpiperidin-4-one
Catalog No.:BCN6504
CAS No.:133568-79-3
- Pseudolarolide Q2
Catalog No.:BCN8092
CAS No.:1338366-22-5
- EPZ004777
Catalog No.:BCC2218
CAS No.:1338466-77-5
- OTS514
Catalog No.:BCC4024
CAS No.:1338540-55-8
- OTS964
Catalog No.:BCC4025
CAS No.:1338545-07-5
- Safinamide
Catalog No.:BCC1915
CAS No.:133865-89-1
- Valnemulin HCl
Catalog No.:BCC4746
CAS No.:133868-46-9
- Soyasaponin Ac
Catalog No.:BCN2897
CAS No.:133882-74-3
- Eicosyl ferulate
Catalog No.:BCN4712
CAS No.:133882-79-8
- ML224
Catalog No.:BCC5596
CAS No.:1338824-21-7
- Kansuiphorin C
Catalog No.:BCN3764
CAS No.:133898-77-8
- Rimantadine
Catalog No.:BCC4938
CAS No.:13392-28-4
- Aristololactam I
Catalog No.:BCN2456
CAS No.:13395-02-3
Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation.[Pubmed:21892191]
Nature. 2011 Sep 4;477(7365):477-81.
PPARgamma is the functioning receptor for the thiazolidinedione (TZD) class of antidiabetes drugs including rosiglitazone and pioglitazone. These drugs are full classical agonists for this nuclear receptor, but recent data have shown that many PPARgamma-based drugs have a separate biochemical activity, blocking the obesity-linked phosphorylation of PPARgamma by Cdk5. Here we describe novel synthetic compounds that have a unique mode of binding to PPARgamma, completely lack classical transcriptional agonism and block the Cdk5-mediated phosphorylation in cultured adipocytes and in insulin-resistant mice. Moreover, one such compound, SR1664, has potent antidiabetic activity while not causing the fluid retention and weight gain that are serious side effects of many of the PPARgamma drugs. Unlike TZDs, SR1664 also does not interfere with bone formation in culture. These data illustrate that new classes of antidiabetes drugs can be developed by specifically targeting the Cdk5-mediated phosphorylation of PPARgamma.